Sign in

PCSA on Nasdaq

Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc. is an American pharmaceutical preparations company based in Vero Beach.2 Its shares trade on Nasdaq under the symbol PCSA.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with ZIOPHARM Oncology, One World Products, Inc. or Aspire-Lakewood Holdings, Inc., or pick any stock.

  • TickerPCSA on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersVero Beach, United States2
  • Incorporated inDE3
  • Business address601 21St Street, Suite 300, Vero Beach, Fl 329603
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI529900A51HZIE4XJB9602
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o National Registered Agents, Inc.,1209 Orange Street, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 49610942

See how the biggest companies compare on our leaderboards

(“NGC”) small molecules, one of which is currently in a Phase 2 trial, while the other is in pre-clinical development.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-367.1%Return on equity6

Financial statements

Revenue78$0 in 2022
02021: $0$020212022: $0$02022
Operating income97810-$27.5M in 2022+599% since 2019
-$30.0M-$20.0M-$10.0M02019: -$3.9M-$3.9M20192020: -$15.1M-$15.1M2020+285%2021: -$12.1M-$12.1M2021−20%2022: -$27.5M-$27.5M2022+127%
Net income97810-$27.4M in 2022+717% since 2019
-$30.0M-$20.0M-$10.0M02019: -$3.4M-$3.4M20192020: -$14.4M-$14.4M2020+329%2021: -$11.4M-$11.4M2021−21%2022: -$27.4M-$27.4M2022+140%

Every line of the income statement as filed: the last 2 fiscal years, latest first.13

Period ending2025-12-312024-12-31
Research and development expenses$7.8M$7.3M
General and administrative expenses$6.2M$4.8M
Operating Loss-$14.0M-$12.1M
Other income$20.0K
Unrealized gain on digital assets at fair value$295.2K
Interest and dividend income, net$109.5K$201.1K
Net Operating Loss Before Income Tax Benefit-$13.6M-$11.9M
Net Loss-$13.6M-$11.9M
Net Loss Per Common Share - Basic-$10.36-$96.78
Net Loss Per Common Share - Diluted-$10.36-$96.78
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic1.3M shares122.4K shares
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted1.3M shares122.4K shares

Compare Processa Pharmaceuticals, Inc. with another company

Corporate structure

Processa Pharmaceuticals, Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Processa Pharmaceuticals, Inc.

  • Soleus Capital Master Fund, L.P. Filed SCHEDULE 13G on Processa Pharmaceuticals, Inc., latest Aug 18, 2026
  • CVI Investments, Inc. Filed SCHEDULE 13G/A on Processa Pharmaceuticals, Inc., latest May 15, 2026 (4 filings since Jun 24, 2025)
  • Chiliz Group Ltd. Filed SCHEDULE 13D/A on Processa Pharmaceuticals, Inc., latest Feb 23, 2026 (3 filings since Aug 13, 2025)
  • INTRACOASTAL CAPITAL, LLC Filed SCHEDULE 13G/A on Processa Pharmaceuticals, Inc., latest Feb 13, 2026 (3 filings since Jun 23, 2025)
  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Processa Pharmaceuticals, Inc., latest Aug 14, 2025 (2 filings since May 15, 2025)
  • 3i, LP Filed SCHEDULE 13G on Processa Pharmaceuticals, Inc., latest Jun 23, 2025
  • Processa Pharmaceuticals, Inc. Vero Beach, Florida, United States
    • Processa Therapeutics LLC Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Processa Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$3.8K13 Dec 31, 2025$5.0K13 Dec 31, 2024−24.0%
Operating-lease assets (leased space)$70.7K13 Dec 31, 2024$146.1K6 Dec 31, 2023−51.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$5.5M13 Dec 31, 2025$1.2M13 Dec 31, 2024+364.8%

Properties, in its own words

We maintain our principal executive office at 601 21st Street, Suite 300 Vero Beach, FL 32960 pursuant to a virtual office agreement.

Item 2 of the 10-K filed Mar 18, 2026.5

Leadership

Who has led Processa Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. George K. Ng2023–now

Chief financial officer

  1. James H. Stanker2020–2024
  2. Russell Skibsted2024–now

Chief operating officer

  1. Robert Michael Floyd2020–2023
2025
Board members and other officers (10)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Processa Therapeutics LLC Delaware4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Heatwurx, Inc.Oct 28, 2011 to Oct 20, 20173

Timeline

  1. Oct 5, 20268-K Other events28
  2. Aug 4, 20268-K Executive or director change; Shareholder vote29
  3. Jul 29, 20268-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale30
  4. Apr 30, 20268-K Executive or director change31
  5. Feb 19, 20268-K Ended a material agreement32
  6. Jan 7, 20268-K Other events33
  7. Dec 15, 20258-K Change to shareholders' rights; Bylaws or fiscal year changed34
  8. Sep 16, 20258-K Bylaws or fiscal year changed; Shareholder vote35
  9. Sep 12, 20258-K Shareholder vote36
  10. Sep 10, 20258-K Shareholder vote37
  11. Sep 2, 20258-K Shareholder vote38
  12. Aug 25, 20258-K Other events39
  13. Aug 9, 2023New chief executive George K. Ng becomes CEO14
  14. Mar 29, 2011Founded Processa Pharmaceuticals, Inc. is founded2

Calendar

Coming up

  1. Nov 5, 2026Reports results for the quarter ending Sep/202640

When it reported results

  1. Mar 31, 2023Reported quarterly or annual results41
  2. Nov 8, 2022Reported quarterly or annual results42
  3. Aug 12, 2022Reported quarterly or annual results43

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

423 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 77 major events, 246 insider forms, 14 large holders, 64 other. The latest 20:

  1. Oct 9, 2026PRE 14A EDGAR
  2. Oct 9, 2026PRE 14A EDGAR
  3. Oct 9, 2026S-3 EDGAR
  4. Oct 5, 20268-K/A EDGAR
  5. Aug 18, 2026SCHEDULE 13G EDGAR
  6. Aug 14, 202610-Q EDGAR
  7. Aug 11, 20264 EDGAR
  8. Aug 4, 20268-K EDGAR
  9. Jul 30, 20264 EDGAR
  10. Jul 30, 20263 EDGAR
  11. Jul 29, 20268-K EDGAR
  12. Jul 28, 20264 EDGAR
  13. Jul 28, 20264 EDGAR
  14. Jul 28, 20264 EDGAR
  15. Jul 28, 20264 EDGAR
  16. Jul 28, 20264 EDGAR
  17. Jul 28, 20264 EDGAR
  18. Jul 28, 20264 EDGAR
  19. Jul 28, 20264 EDGAR
  20. Jul 1, 20264 EDGAR

The 423 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

69 open-market trades by officers, directors and large owners since October 2021: 66 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 1, 2026Ng George KChief Executive OfficerBuy3,057$1.93$5.9KForm 4
Jun 30, 2026Guy WendyChief Administrative OfficerBuy2,436$1.93$4.7KForm 4
Jun 30, 2026Lin PatrickChief Business - Strategy OffBuy2,106$1.93$4.1KForm 4
Jun 30, 2026SKIBSTED RUSSELLChief Financial OfficerBuy3,277$1.93$6.3KForm 4
Jun 30, 2026Young DavidPres. Research & DevelopmentBuy2,531$1.93$4.9KForm 4
Jun 15, 2026Young DavidPres. Research & DevelopmentBuy2,067$2.22$4.6KForm 4
Jun 15, 2026SKIBSTED RUSSELLChief Financial OfficerBuy2,654$2.22$5.9KForm 4
Jun 15, 2026Ng George KChief Executive OfficerBuy2,465$2.22$5.5KForm 4
Jun 15, 2026Lin PatrickChief Business - Strategy OffBuy1,831$2.22$4.1KForm 4
Jun 15, 2026Guy WendyChief Administrative OfficerBuy2,118$2.22$4.7KForm 4
May 29, 2026Young DavidPres. Research & DevelopmentBuy1,786$2.57$4.6KForm 4
May 29, 2026SKIBSTED RUSSELLChief Financial OfficerBuy2,292$2.57$5.9KForm 4
May 29, 2026Ng George KChief Executive OfficerBuy2,129$2.57$5.5KForm 4
May 29, 2026Lin PatrickChief Business - Strategy OffBuy1,582$2.57$4.1KForm 4
May 29, 2026Guy WendyChief Administrative OfficerBuy1,829$2.57$4.7KForm 4
May 15, 2026Ng George KChief Executive OfficerBuy1,843$2.97$5.5KForm 4
May 15, 2026Young DavidPres. Research & DevelopmentBuy1,545$2.97$4.6KForm 4
May 15, 2026Lin PatrickChief Business - Strategy OffBuy1,369$2.97$4.1KForm 4
May 15, 2026Guy WendyChief Administrative OfficerBuy1,583$2.97$4.7KForm 4
May 15, 2026SKIBSTED RUSSELLChief Financial OfficerBuy1,984$2.97$5.9KForm 4

All 69 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025George Ng52$400.0K$673.3K50
2025Russell Skibsted67$400.0K$566.8K50
2025Sian Bigora$367.8K$495.1K50
2024Chief Executive Officer$400.0K$521.0K50
2024Former Chief Development and Regulatory Officer$290.9K$328.3K50
2024Chief Financial Officer$183.3K$244.2K50

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Connective Capital Management, LLC85,274$163.7K0.1%+14,538
Stonepine Capital Management, LLC55,000$105.6K0.1%No change
Geode Capital Management, LLC22,090$42.4K0.0%−2,818
Citadel Advisors LLC21,306$40.9K0.0%New
StoneX Group Inc.11,437$29.6K0.0%New
XTX Topco Ltd13,292$25.5K0.0%New
Jane Street Group, LLC13,264$25.5K0.0%New
Vanguard Capital Management LLC12,729$24.4K0.0%No change
Vanguard Fiduciary Trust Co10,857$20.8K0.0%No change
UBS Group AG7,794$15.0K0.0%+5,263
Tower Research Capital LLC (TRC)2,499$4.8K0.0%+1,581
Jones Financial Companies Lllp7$130.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Processa Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARProcessa Pharmaceuticals, Inc.1
  • CIK0001533743
  • Employer ID (EIN)45-15397855
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address601 21St Street, Suite 300, Vero Beach, FL 329601
  • Phone443-776-31331
  • Shares outstanding2,793,386 as of Aug 7, 202612
  • Public float$8.1M as of Jun 30, 20255
  • AuditorCherry Bekaert LLP, Tampa, Florida PCAOB ID 677; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceOct 28, 20111
  • Filings698 in all: 4 (238), 8-K (156), 10-Q (40), 4/A (38), CORRESP (25), UPLOAD (19), 3 (16), D (14)1
    All 46 form types

    S-1/A (14), 10-K (13), DEF 14A (10), EFFECT (9), DEFA14A (8), PRE 14A (7), 8-K/A (6), S-1 (6), S-8 (6), SCHEDULE 13G/A (6), 10-K/A (5), 424B5 (5), NT 10-Q (5), SCHEDULE 13G (5), 3/A (4), 424B3 (4), 424B4 (4), S-3 (4), DEF 14C (3), NT 10-K (3), PRE 14C (3), SC 13G (3), D/A (2), SC 13G/A (2), SCHEDULE 13D/A (2), 10-Q/A (1), 8-A12B (1), ARS (1), CERT (1), DEFR14A (1), DRS (1), DRSLTR (1), PRER14A (1), RW (1), RW WD (1), S-1MEF (1), SC 13D (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Mar 18, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Jun 18, 2026
    Latest 8-K (8-K) Aug 4, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.0001 par value per sharePCSAThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 18, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks Processa Pharmaceuticals, Inc. names in Item 1A of its 10-K filed Mar 18, 2026: 53 risks under these headings, as written.5

  • We are providing the following summary of the risk factors contained in our Form 10-K to enhance the readability and accessibility of our risk factor disclosures. We encourage our stockholders to carefully review the full risk factors contained in this Form 10-K in their entirety for additional information regarding the risks and uncertainties that could cause our actual results to vary materially from our recent results or from our anticipated future results.
  • Risks Related to Our Financial Position and Need for Additional Capital
  • Risks Relating to Clinical Development and Commercialization of Our Product Candidates
  • Risks Related to our Digital Asset Treasury Strategy
  • Risks Relating to Our Intellectual Property Rights
  • General Company-Related Risks
  • Risks Related to Ownership of Our Common Stock
  • We need to raise additional capital to fund our operations.
  • We have incurred a history of operating losses and expect to continue to incur substantial costs for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability. Our financial situation creates doubt whether we will continue as a going concern.
  • We have limited cash resources and will require additional financing.
  • We will need to raise additional capital to complete the development efforts for NGC-Cap and/or NGC-Iri. If we are unable to raise capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.
  • Our financial statements contain a statement regarding a substantial doubt about our ability to continue as a going concern.
The other 47 risks
  • Our ability to use our net operating loss carryforwards and other tax attributes may be limited.
  • Our licenses are subject to termination by the licensor in certain circumstances and any termination of a license agreement would result in a loss of important rights and have a material adverse impact on our business and prospects.
  • We currently do not have, and may never develop, any FDA-approved, licensed or commercialized products.
  • We depend entirely on the successful development of our product candidates, which have not yet demonstrated efficacy for their target indications in clinical trials. We may never be able to demonstrate efficacy for our product candidates, thus preventing us from licensing, obtaining marketing approval by any regulatory agency, and/or commercializing our product(s).
  • We must successfully complete clinical trials for our product candidates before we can apply for marketing approval.
  • We have little corporate history of conducting clinical trials. Our planned clinical trials or those of our collaborators may reveal significant adverse events, toxicities or other side effects not seen in our preclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.
  • Disruptions at the FDA and other government agencies could hinder new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business.
  • Even if we receive regulatory approval for any of our product candidates, we may not be able to successfully license or commercialize the product and the revenue that we generate from its sales, if any, may be limited.
  • We are completely dependent on third parties to manufacture our product candidates, and our commercialization of our product candidates could be halted, delayed or made less profitable if those third parties fail to obtain manufacturing approval from the FDA or comparable foreign regulatory authorities, fail to provide us with sufficient quantities of our product candidates or fail to do so at acceptable quality levels or prices.
  • Even if we obtain marketing approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expenses.
  • Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
  • Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
  • We could face competition from other biotechnology and pharmaceutical companies, and our operating results would suffer if we fail to innovate and compete effectively.
  • We rely on third parties to conduct clinical trials for our product candidates. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize any of our product candidates and our business would be substantially harmed.
  • Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
  • Even though we may apply for orphan drug designation for a product candidate, we may not be able to obtain orphan drug marketing exclusivity.
  • Although we may pursue expedited regulatory approval pathways for a product candidate, it may not qualify for expedited development or, if it does qualify for expedited development, it may not actually lead to a faster development, regulatory review or approval process.
  • Third-party coverage and reimbursement, health care cost containment initiatives and treatment guidelines may constrain our future revenues.
  • Legal, regulatory and legislative changes with respect to reimbursement, pricing and contracting may adversely affect our business and future prospects.
  • We may face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate.
  • If any of our product candidates are approved for marketing and we are found to have improperly promoted off-label uses, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, product liability claims and significant fines, penalties and sanctions, and our brand and reputation could be harmed.
  • We may choose not to continue developing or commercializing any of our product candidates at any time during development or after approval, which would reduce or eliminate our potential return on investment for those product candidates.
  • Changes in U.S. and international trade policies, particularly with respect to China, Europe and India may adversely impact our business and operating results.
  • Investments in Digital Assets are substantially speculative and have a significant risk of resulting in a loss compared to other forms of investment.
  • Digital Assets have historically experienced, and are expected to continue to experience, high price volatility which may influence our financial results and the market price of our common stock.
  • We may be unable to successfully implement our Digital Asset Strategy.
  • Our Digital Asset holdings will be less liquid than existing cash and cash equivalents and may not be able to serve as a source of liquidity to the same extent as cash and cash equivalents.
  • If we or our third-party service providers experience a security breach or cyberattack and unauthorized parties obtain access to our Digital Assets, we may lose some or all of our Digital Assets and our financial condition and results of operations could be materially adversely affected.
  • We face risks relating to the custody of our Digital Assets, including the loss or destruction of private keys required to access our Digital Assets, and cyberattacks or other data loss relating to our Digital Assets.
  • Our custodially-held Digital Assets may become part of the custodian’s insolvency estate if one or more of our custodians enters bankruptcy, receivership or similar insolvency proceedings.
  • Digital Assets held by us are not subject to FDIC or SIPC protections.
  • Digital Assets are novel assets, and are subject to significant legal, commercial, regulatory, and technical uncertainty.
  • We could be subject to legal or regulatory action, including fines, in the event the SEC, a foreign regulatory authority, or a court were to determine that a digital asset held by us is a “security” under applicable laws.
  • We cannot ensure protection of our licensed intellectual property rights.
  • Our product candidates may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development and commercialization efforts.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Litigation or legal proceedings could expose us to significant liabilities and have a negative impact on our business.
  • If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to identify and develop new or next generation product candidates will be impaired, could result in loss of markets or market share and could make us less competitive.
  • If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions, interruptions or disruptions to operations or clinical trials, reputational harm, litigation, fines and penalties.
  • We are exposed to cyber-attacks and data breaches, including the risks and costs associated with protecting our systems and maintaining integrity and security of our business information, as well as personal data of our guests, employees and business partners.
  • Our failure to maintain compliance with Nasdaq’s continued listing requirements could result in the delisting of our Common Stock.
  • Future equity offerings, license transactions or acquisitions may dilute our existing stockholders’ ownership and/or have other adverse effects on our operations.
  • Our common stock price is volatile.
  • We are a “smaller reporting company,” and the reduced disclosure requirements applicable to us as such may make our common stock less attractive to our stockholders and investors.
  • We do not currently intend to pay dividends to our stockholders in the foreseeable future, and consequently, your ability to achieve a return on your investment will depend on appreciation in our value.
  • Provisions in our corporate documents and Delaware law could have the effect of delaying, deferring, or preventing a change in control of us, even if that change may be considered beneficial by some of our stockholders.
  • Provisions in our bylaws provide for indemnification of officers and directors, which could require us to direct funds away from our business and the development of our product candidates.

Legal proceedings

From time to time, we may become involved in litigation or other legal proceedings. Except as described below, we are not currently a party to any material litigation or legal proceedings. Regardless of outcome, any litigation that we may become involved in can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

On May 7, 2024, the Company received notification from Elion purporting to terminate the license agreement by and between the Company and Elion as a result of the Company’s alleged breach thereof. The Company believes that Elion’s claims are without merit and disputes that the license agreement has been validly terminated. On July 5, 2024, the Company filed a complaint in the Commercial Division of the Supreme Court of the State of New York, New York County seeking monetary damages, declaratory judgement and injunctive relief. On August 14, 2024, the Company received Elion’s answer and counterclaims. On October 10, 2024, the Company filed its response to Elion’s counterclaims. The Company intends to enforce its rights under the license agreement and will pursue such other remedies as it determines are appropriate. The discovery phase of the matter commenced several months ago and is ongoing.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
    SEC EDGAROther events
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50